Health Claims Due Diligence: Supplement and FMCG M&A

In consumer health, supplements, and fast-moving consumer goods (FMCG) transactions, aggressive marketing often conceals material regulatory exposure. High-growth direct-to-consumer (D2C) brands frequently scale top-line revenue through bold health claims across e-commerce storefronts, social media channels, and packaging. When corporate acquirers or private equity funds evaluate these targets, treating regulatory oversight as a generic corporate compliance check creates severe blind spots.

Product and market regulation governs the commercial core of a brand: what a product contains, how it is classified, where it can be sold, and what functional benefits can legally be promised to consumers. Unlike standard corporate governance reviews that focus on internal policies or anti-bribery measures, a dedicated regulatory compliance due diligence stream examines whether the target's underlying revenue model relies on non-compliant marketing claims or unauthorized formulations.

The financial consequences of unverified claims post-close can be severe. Regulatory enforcement from agencies such as the FDA, EFSA, or national advertising authorities can trigger immediate product seizures, mandatory packaging recalls, and injunctions against digital advertising. In serious scenarios, acquirers face substantial inventory write-downs, operational disruption, and the expense of comprehensive brand repositioning that erodes projected deal returns.

• Forced product withdrawals and inventory obsolescence triggered by non-compliant ingredients or unauthorized claims
• Substantial rebranding and packaging reprint expenses following regulatory enforcement actions
• E-commerce channel suspensions, merchant account freezes, and paid ad account bans that throttle commercial acquisition
• Significant valuation adjustments and post-closing indemnity claims linked to undisclosed regulatory investigations

Deal teams must therefore evaluate product-level compliance as an essential component of commercial sustainability and valuation integrity, ensuring that commercial growth is backed by defensible technical and scientific dossiers.

A comprehensive health claims due diligence framework begins by systematically mapping every SKU in the target's product catalogue against the applicable regulatory regimes across each target market. Regulatory boundaries vary substantially across jurisdictions, meaning a compliant structure-function claim in one country may constitute an illegal medicinal claim in another. Regimes that do not apply to a specific geographic footprint or product category should be marked explicitly as N/A to maintain analytical clarity.

Within the European Union, food supplements and fortified FMCG products are subject to harmonized standards under Regulation (EC) No 1924/2006 on nutrition and health claims made on foods, which applies to claims made in the labelling, presentation and advertising of foods delivered to the final consumer. Nutrition claims are permitted only if they are listed in the Annex to the regulation, while health claims are prohibited unless authorised and included in the lists provided for in Articles 13 and 14, and every claim must be based on and substantiated by generally accepted scientific data assessed with input from the European Food Safety Authority (EFSA). Diligence teams must cross-examine whether the specific wording used on product packaging and digital webshops strictly reflects authorized claim conditions.

In the United States, dietary supplements operate under the Dietary Supplement Health and Education Act (DSHEA) framework administered by the FDA. Under section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 101.93, the manufacturer, packer, or distributor of a dietary supplement bearing a structure-function claim, a general well-being claim, or a classical nutrient deficiency claim must notify the FDA no later than 30 days after first marketing the product. Furthermore, the person making the claim must have substantiation that it is truthful and not misleading, and the label must carry the mandatory statutory disclaimer stating that the product is not intended to diagnose, treat, cure, or prevent any disease.

Conducting effective private equity due diligence on consumer health assets requires deal teams to verify both pre-market notifications and ongoing substantiation dossiers for each active SKU.

Target evaluation in the supplements and wellness sectors regularly uncovers recurring compliance gaps that distort unit economics and expose buyers to regulatory liabilities. A primary area of concern is borderline product misclassification. The MHRA treats a medicinal product as any substance presented as having properties for preventing or treating disease in human beings, with disease defined in Regulation 8 of the Human Medicines Regulations 2012 as including any injury, ailment or adverse condition, whether of body or mind. Food supplements containing familiar substances such as vitamins, amino acids or minerals normally fall under food law rather than medicines control unless they are presented for medicinal uses, and the MHRA assesses explicit and implicit claims across labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews when deciding status. Where a supplement is judged to be an unlicensed medicine, outcomes range from amended claims or reformulation through to removal from sale and, in unresolved cases, escalation towards prosecution.

Another frequent defect is the divergence between approved physical packaging and aggressive online marketing copy. Fast-growing brands often maintain conservative, compliant text on their physical packaging while publishing non-compliant therapeutic assertions on webshop landing pages, customer review sections, and paid advertising funnels to maximize conversion rates.

Identifying these red flags early enables investment committees to quantify operational remedies, renegotiate purchase price terms, or require pre-closing corrective actions from the seller.

To uncover regulatory vulnerabilities before finalizing transaction terms, deal teams must demand comprehensive technical and marketing dossiers in the virtual data room. Requesting standard corporate records is insufficient; acquirers require granular evidence validating formulation integrity, manufacturing compliance, and marketing defensibility.

In the United Kingdom, following the end of the Brexit transition period on 1 January 2021, commercial health and nutrition claims made in Great Britain must appear on the Great Britain nutrition and health claims (GB NHC) register. Advertisers must hold documentary evidence demonstrating that their products meet the specific conditions of use outlined in the GB NHC register and comply with Section 15 of the ASA CAP Code. Diligence teams must obtain and audit these substantiation files against live commercial campaigns.

• Complete quantitative formulations and ingredient specifications detailing active dosages and purity profiles
• Master packaging artwork, physical label proofs, and multi-language packaging variants for all operating jurisdictions
• Copies of regulatory filings, including FDA 30-day structure-function claim notifications and national product registrations
• Scientific substantiation dossiers, published clinical studies, and technical literature supporting each advertised functional claim
• Comprehensive digital marketing archive, including product landing pages, email marketing funnels, and paid social advertisements
• Influencer contracts, campaign briefs, and compliance monitoring records for external brand ambassadors
• Log of all regulatory correspondence, courtesy letters, warning notices, and customer health-related complaints

Reviewing these records alongside a specialized website compliance audit ensures that public e-commerce channels reflect the formal regulatory approvals documented in the data room.

Conducting thorough regulatory and product diligence across extensive consumer portfolios requires processing hundreds of technical specifications, formulation sheets, marketing decks, and online product listings. Data Room Ingestion accelerates this phase by automatically connecting to virtual data rooms, ingesting unstructured files, and converting dense regulatory filings and ingredient disclosures into a structured knowledge base.

Once ingested, the AI-Analysis Engine cross-references product formulations against active marketing copy, social media archives, and e-commerce product pages. By evaluating advertised functional benefits against established regulatory registers, such as EU Regulation 1924/2006 and the GB NHC register, the engine rapidly spots non-compliant disease claims, unauthorized nutrient claims, and ingredient dosage discrepancies.

• Rapid automated classification of batch records, formulation dossiers, and marketing collateral
• Cross-checking webshop copy against packaging artwork to detect unapproved therapeutic assertions
• Systematic detection of borderline medicinal claims across digital acquisition funnels
• Automated generation of structured risk registers with source citations linking directly to data room files

Through the Risk Radar, these findings are categorized by regulatory severity, financial materiality, and transaction relevance. This gives deal leads and advisory partners a clear, evidence-backed overview of product-level liabilities, helping teams structure targeted buyer inquiries and valuation protections.

AI-powered due diligence and deal intelligence platforms are designed to assist deal teams, corporate development leads, and advisory professionals in structuring complex transaction data. They provide automated evidence extraction, issue spotting, and risk register preparation to streamline transaction workflows.

Plausity does not provide legal advice, regulatory opinions, or formal compliance certifications. The platform is not a substitute for qualified legal counsel, specialized regulatory consultants, or clinical experts. All analytical findings, discrepancy flags, and risk assessments generated during due diligence must be reviewed and confirmed by qualified legal and regulatory advisors before making investment or operational decisions.

• No Legal Advice: platform outputs are for informational and analytical diligence support only
• No Compliance Certification: platform findings do not constitute regulatory approval or statutory clearance
• Advisor Confirmation Required: all identified red flags and regulatory risks must be validated by qualified legal counsel
• Evidence Structuring Support: automated document analysis and source grounding exist to empower professional advisory teams, not to replace them

Integrating automated analysis with expert legal validation ensures that investment decisions rest on verified evidence while maintaining rigorous professional governance.

To incorporate health claims due diligence into an active transaction, deal teams should establish a structured multi-workstream process at the outset of the confirmatory phase. Integrating product-level compliance checks early prevents late-stage transaction delays and provides quantifiable data for purchase agreement negotiations.

• Configure Data Room Ingestion to scan all uploaded product dossiers, regulatory notices, and marketing assets
• Map active product lines against regional regulatory frameworks, marking non-applicable jurisdictions as N/A
• Deploy the AI-Analysis Engine to compare digital marketing claims across e-commerce storefronts against official formulation dossiers
• Examine surfaced discrepancies in the Risk Radar, classifying issues by operational and financial materiality
• Synthesize structured findings across four distinct pillars: evidence, issue, risk, and recommended remediation
• Utilize the Collaboration Hub to coordinate findings with external legal advisors, regulatory consultants, and target management
• Incorporate validated regulatory risks and remediation costs into the final investment committee memorandum and legal due diligence report

By coupling automated evidence structuring with qualified legal review, acquirers can confidently evaluate high-growth supplement and FMCG brands while protecting post-closing value.

Plausity is an AI-native due diligence and deal intelligence platform that helps M&A advisory firms, VC and PE funds, corporate development teams and family office investment teams structure evidence, findings and questions across a data room. Plausity does not provide legal advice, does not issue compliance certification and does not replace qualified legal or regulatory advisors — it supports evidence structuring, issue spotting, source grounding and risk register preparation, and all findings should be confirmed by qualified legal or regulatory advisors.

To explore the underlying capabilities, see the Plausity AI analysis engine and the findings and risk intelligence product page. For team-level workflows, see how VC and PE funds and M&A advisory firms use Plausity across live deals.

1. eur-lex.europa.eu
2. ecfr.gov
3. gov.uk
4. asa.org.uk